论文部分内容阅读
目的探讨氨溴索联合人免疫球蛋白静脉滴注对小儿重症肺炎疗效及肺功能的影响。方法回顾性分析2012年12月—2015年6月该院诊治的90例重症肺炎患儿临床资料,按照不同治疗方式分为二组(各45例),对照组予常规利巴韦林治疗,在此基础上,观察组予氨溴索联合人免疫球蛋白静脉滴注治疗,对比二组临床情况。结果观察组啰音、喘咳、发热等主要症状缓解时间及住院时间均短于对照组(P<0.01);观察组治疗后主要肺功能指标(FEV1、PEF、FVC、PImax、PEmax)均发生显著改善,且优于对照组(P<0.01);观察组不良反应13.33%低于对照组35.35%(P<0.05)。结论氨溴索联合人免疫球蛋白静脉滴注治疗小儿重症肺炎疗效显著,可有效改善患儿肺功能,且可减少不良反应。
Objective To investigate the effect of ambroxol combined with human immunoglobulin intravenous drip on the efficacy and pulmonary function of children with severe pneumonia. Methods The clinical data of 90 severe pneumonia children diagnosed and treated in this hospital from December 2012 to June 2015 were retrospectively analyzed. The patients were divided into two groups (45 cases each) according to different treatment methods. The control group was treated with conventional ribavirin, On this basis, the observation group to ambroxol combined with human immunoglobulin intravenous infusion treatment, the clinical situation of the two groups were compared. Results The relief time and length of hospital stay of the observation group were shorter than those of the control group (P <0.01). The main pulmonary function indexes (FEV1, PEF, FVC, PImax, PEmax) (P <0.01). The adverse reaction rate in the observation group was 13.33% lower than that in the control group (35.35%, P <0.05). Conclusion Ambroxol combined with human immunoglobulin intravenous infusion of severe pneumonia in children with significant effect, can effectively improve children’s lung function, and reduce adverse reactions.